COCH · Envoy Medical, Inc. · Insider Trading

Options to purchase 62,500 shares vest on 8/24/2027, and 187,500 shares vest pro rata on the 24th of each month thereafter for 36 consecutive months.

Options to purchase 250,000 shares vest on 6/19/27, and 750,000 shares vest pro rata on the 19th of each month thereafter for 36 consecutive months.

Each restricted stock unit represents a contingent right to receive one share of Envoy Medical, Inc. Class A Common Stock.

All restricted stock units subject to the RSU Award Grant Notice dated June 19, 2026, will vest as of the date of the official notification by the U.S. Food and Drug Administration (FDA) that it has granted approval (including approval with conditions) for its Acclaim cochlear implant, provided that such announcement occurs during the performance period beginning June 19, 2026 and ending on June 18, 2030.

These shares were acquired under the Envoy Medical, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Beginning on 5/15/2026, options to purchase Class A Common Stock will vest pro rata on the 15th of each month for 36 consecutive months.

Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.

The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date").

The Series A-2 Warrants expire on the earlier of (i) the sixty-month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has received U.S. Food and Drug Administration approval for its Acclaim cochlear implant (the "Series A-2 Milestone Event").

Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.

Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.

Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.

Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.

The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date").

The Series A-1 Warrants expire on the earlier of (i) the twenty-four month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration for its Acclaim cochlear implant (the "Series A-1 Milestone Event").

Options to purchase 3,750 shares vest on 2/5/2027, and 11,250 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.

Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.

These shares were acquired under the Envoy Medical, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 8/27/2024 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 7/22/2024 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 8/27/2024 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally purchased on 2/27/2024 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 3/11/2025 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 12/11/2024 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 5/23/2024 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 6/26/2025 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 3/11/2025 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 6/26/2025 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 7/22/2024 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 5/23/2024 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally purchased on 2/27/2024 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 12/11/2024 and is fully exercisable.

Fully exercisable.

GAT Funding, LLC is an entity controlled by the Reporting Person.

In connection with the promissory note issuance effective March 6, 2025 and the closing of the final funding on June 26, 2025, this warrant was issued to GAT Funding, LLC, as described in more detail in Item 1.01 of the Issuer's 8-K as filed with the SEC on July 2, 2025.

GAT Funding, LLC is an entity controlled by the Reporting Person.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.44 to $1.4799 inclusive. The reporting person undertakes to provide Envoy Medical, Inc., any security holder of Envoy Medical, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.4981 inclusive. The reporting person undertakes to provide Envoy Medical, Inc., any security holder of Envoy Medical, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

These shares were acquired under the Envoy Medical, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6345 to $1.65 inclusive. The reporting person undertakes to provide Envoy Medical, Inc., any security holder of Envoy Medical, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.